Clinical Trial

A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

Study acronym: BREADTH
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma. The main goals of this study are to investigate how effective KT-621 is at treating uncontrolled moderate to severe eosinophilic asthma, the safety and tolerability of KT-621, and how KT-621 behaves in the body.
Protocol Amendment History 3 changes
notable Trial sites expanded: 27 -> 58 locations 2026-06-30
notable Trial sites expanded: 17 -> 27 locations 2026-05-19
notable Trial sites expanded: 9 -> 17 locations 2026-04-24
Trial Details
NCT Number NCT07323654
Lead Sponsor Kymera Therapeutics, Inc.
Conditions Eosinophilic Asthma
Enrollment 264 participants
Start Date 2026-01-28
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-29